Topical recombinant human nerve growth factor (rhNGF) is FDA-approved to treat patients with neurotrophic keratitis (NK), but current clinical trial data only encompasses 1 year of follow up. We hypothesize that a single course of rhNGF can have a long-term, persistent effect on NK healing and related clinical parameters. Therefore, we evaluated the long-term efficacy of rhNGF in a retrospective, consecutive, observational case series from a single-center setting over a 4-year period.
The long-term clinical efficacy of recombinant human nerve growth factor in the treatment of neurotrophic keratitis / Bruscolini, Alice; Sacchetti, Marta; Moramarco, Antonietta; Albanese, GIUSEPPE MARIA; Cerini, Alberto; Lambiase, Alessandro. - In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. - ISSN 0146-0404. - 62:8(2021).
The long-term clinical efficacy of recombinant human nerve growth factor in the treatment of neurotrophic keratitis
alice bruscoliniPrimo
;Marta SacchettiSecondo
;Antonietta Moramarco;Giuseppe Maria Albanese;Alberto CeriniPenultimo
;alessandro lambiase
Ultimo
2021
Abstract
Topical recombinant human nerve growth factor (rhNGF) is FDA-approved to treat patients with neurotrophic keratitis (NK), but current clinical trial data only encompasses 1 year of follow up. We hypothesize that a single course of rhNGF can have a long-term, persistent effect on NK healing and related clinical parameters. Therefore, we evaluated the long-term efficacy of rhNGF in a retrospective, consecutive, observational case series from a single-center setting over a 4-year period.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
